Drugs of Abuse Rapid Testing Kit, 10-Drug Panel, Dipcard, 5 Minute Results, 25 Tests Per Box

The McKesson Drugs of Abuse Testing Kit is used to screen human urine for multiple drugs and drug metabolites at specific cutoff levels. This rapid, all-in-one dipcard provides preliminary qualitative results, indicating whether a tested substance is detected at or above its cutoff rather than measuring its exact concentration. It can support drug screening in clinical care, substance-use treatment, and other authorized testing programs.

Key features:

• Multi-drug screening: The listed panel includes amphetamines (AMP), barbiturates (BAR), benzodiazepines (BZO), cocaine (COC), methamphetamine (mAMP/MET), methadone (MTD), morphine/opiates (OPI), phencyclidine (PCP), tricyclic antidepressants (TCA), and marijuana/hashish (THC).
• Panel options: McKesson’s dipcard range offers panels of up to 12 analytes. The product title lists 10 drug categories; check the specific kit’s labeling to confirm its configuration.
• Low-cutoff opiate screening: The supplied specifications identify MOP300, a morphine/opiate screening cutoff of 300 ng/mL.
• Specimen integrity screening: Combines drug-of-abuse test strips with adulteration testing. These semi-quantitative checks assess oxidants, specific gravity, pH, nitrite, glutaraldehyde, and creatinine to help identify potentially diluted or adulterated urine. The supplied terms “nitrile” and “creatine” appear to mean “nitrite” and “creatinine”; verify against the package insert.
• Detection timing: The supplied information lists a minimum detection time of 2–7 hours after suspected use. Actual detectability varies by drug, dose, metabolism, and urine concentration; this is not a guaranteed detection window.
• Fast results: Results in 5 minutes, when used and read according to the manufacturer’s instructions.
• CLIA-waived: Listed as CLIA-waived; follow the labeling and applicable testing requirements.
• Single-use: Each dipcard is for one use only.
• Package quantity: 25 tests.

Important: Screening results do not establish impairment or diagnose a substance-use disorder. A presumptive positive should be confirmed using a more specific laboratory method, such as GC-MS or LC-MS/MS. A negative result does not rule out drug use.